Unregistered User If this is not your name, click here.
		Contact Us | Order Now | Journals | Bookstore | Register a colleague
	Select a ChannelAcneAIDS and HIVAllergy OtherAlzheimer'sAnaesthesiology OtherAngina Pectoris/MIAnxietyArthritis OtherAsthmaBack PainBacterial InfectionsBladder CancerBone Marrow TransplantationBreast CancerCardiology OtherCataractCell TransplantationCervical CancerCholesterol/Lipid disordersCirrhosisClinical PharmacologyColorectal CancerCongestive Heart FailureContact DermatitisContraceptionCOPDCystic FibrosisDental and Oral DisordersDepressionDermatology OtherDiabetesDialysisEating DisordersElbowEmergency MedicineEndocrinology OtherEpilepsyErectile DysfunctionFibromyalgiaGastro OtherGeneticsGenitourinary OtherGeriatricsGERD/GastritisGlaucomaH. Pylori/UlcerHaematology OtherHair LossHeadachesHepa/Biliary OtherHepatitisHipHRTHypertensionIBDImmunologyInfectious OtherInfertilityIntensive CareIrritable Bowel SyndromeKneeLeukemiasLiver CancerLung CancerLupusLymphomasMelanomaMenopauseMultiple Sclerosis Nephrology OtherNeurologic OtherNutritional / Metabolic OtherOb/Gyn OtherObesityOncology OtherOphth. OtherOphthalmic SurgeryOrgan TransplantationOrthopaedics OtherOsteoarthritisOsteoporosisOtitisOtorhino. OtherOvarian CancerPaediatricsPainPancreatic CancerParkinson'sPregnancyProstate CancerPsychiatry OtherPulmonary OtherRadiologyRenal CancerRenal FailureRespiratory InfectionsRheumatoid arthritisRheumatology OtherRhinitisSchizophreniaShoulderSleep ApnoeaSleep DisordersSpineStrokeSTDsSurgeryThyroid DisordersTransfusionTransplant Surgery OtherTraumaUrinary IncontinenceUrinary tract infectionsVaccinologyVascular DisordersViral Infections

SEARCH   News Bookstore Medline The Web Meetings & Congresses Complete Doctor's Guide    EXPLORE :    All News   All Webcasts   All Cases   All Meetings & Congresses   All Medical Resources New drugs / indications English Dictionary Medical Dictionary Thesaurus Warning | Privacy | Awards  Favourite Journals  Click here to choose your favourite journals  Favourite Sites  Click here to choose your favourite sites  Languages  Select languageEnglishFrançais

NICE Recommends Liraglutide for Diabetes Triple Therapy LONDON -- February 17, 2010 -- The National Institute for Health and Clinical Excellence (NICE) has recommended the use of liraglutide (Victoza), a once-daily injection, for the treatment of type-2 diabetes as part of triple therapy regimens, under latest draft guidance. This latest announcement offers a new alternative for patients who are unable to control their diabetes with current treatments. Patients who are already taking metformin and a sulfonylurea, or metformin and a thiazolidinedione, but still have poor blood glucose control should be offered liraglutide in combination with their current treatments. Patients must also be overweight, with a body mass index (BMI) of 35kg/m2 and over, to be eligible for the drug. However, diabetics who have a BMI below 35kg/m2 could also benefit from the drug if it is considered that its use could help to achieve levels of weight loss that could be beneficial in treating other conditions caused by being obese. George Kassianos, MD, British Cardiovascular Society, Berkshire, United Kingdom, described the approval by NICE of the use of liraglutide in triple therapy as “a very welcome development for primary care physicians.” “Controlling hyperglycaemia and its indicators is not easy. The addition of liraglutide to our formulary will be welcome by patients and will go a long way to helping them achieve their glycaemic goals,” he said. Under the draft guidance, liraglutide is not recommended for use in dual therapy or in the 1.8mg daily dosage. Carole Longson, MD, Health Technology Evaluation Centre, NICE, London, United Kingdom, said: “We are pleased to recommend liraglutide, 1.2 mg daily, as a clinically and cost effective treatment option as part of triple therapy regimens for some patients under restrictions.” “However we felt that there was not sufficient evidence to recommend it in dual therapy regimens for type-2 diabetes mellitus,” she said. “The Committee concluded that there were disparities in the data provided by the manufacturer, particularly regarding the economic analyses of liraglutide in dual therapy regimens for this type of diabetes. The next step for the manufacturer is to consider the committee’s comments and respond to its concerns.” SOURCE: National Institute for Health and Clinical Excellence E-mail this page to a friend or colleague! To print, use this version